These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11235223)

  • 21. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
    Zincke H; Lau W; Bergstralh E; Blute ML
    J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
    Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
    Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
    Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
    Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
    Lau WK; Bergstralh EJ; Blute ML; Slezak JM; Zincke H
    J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome and complications of radical prostatectomy in patients with PSA <10 ng/ml: comparison between the retropubic, perineal and laparoscopic approach.
    Salomon L; Levrel O; Anastasiadis AG; Saint F; de La Taille A; Cicco A; Vordos D; Hoznek A; Chopin D; Abbou CC
    Prostate Cancer Prostatic Dis; 2002; 5(4):285-90. PubMed ID: 12627213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term outcome of radical prostatectomy in an observation period of at least 10 years].
    Fischer C; Schreiber A; Altwein JE
    Aktuelle Urol; 2005 Apr; 36(2):131-5. PubMed ID: 15902573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
    Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
    Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
    Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
    J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
    van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
    Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease.
    Antenor JA; Roehl KA; Eggener SE; Kundu SD; Han M; Catalona WJ
    Urology; 2005 Jul; 66(1):156-60. PubMed ID: 15992903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
    J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical outcome and analysis of radical prostatectomy in clinical stage B and C prostate cancer].
    Miyoshi Y; Uemura H; Mikata K; Ohuchi H; Jinza S; Yao M; Takeda M; Masuda M; Noguchi S; Noguchi K; Kubota Y; Hosaka M
    Hinyokika Kiyo; 2001 Mar; 47(3):163-8. PubMed ID: 11329956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?
    MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
    Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
    Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
    Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of preoperative serum PSA level from 0 to 10 ng/ml on pathological findings and disease-free survival after radical prostatectomy.
    Shekarriz B; Upadhyay J; Bianco FJ; Tefilli MV; Tiguert R; Gheiler EL; Grignon DJ; Pontes JE; Wood DP
    Prostate; 2001 Aug; 48(3):136-43. PubMed ID: 11494329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution of the clinical presentation and outcomes after radical prostatectomy for patients with clinically localized prostate cancer--changing trends over a ten year period.
    Stimac G; Dimanovski J; Trnski D; Katusić J; Ruzić B; Spajić B; Reljić A; Padovan M; Kraus O
    Coll Antropol; 2007 Dec; 31(4):1055-60. PubMed ID: 18217458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.